Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation

TL;DR: Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians and new recommendations addressing atrial fibrillation and thromboembolic risk assessment have been developed.

TL;DR: In this paper, a systematic review of current evidence for the use of the ABC pathway on clinical outcomes was performed, with a pooled prevalence of ABC-adherent management of 21% (95% confidence interval, CI: 13-34%).

TL;DR: The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region.

TL;DR: The next chair and vice-chair will be announced at a special meeting of the American Academy of Anti-Accident and Accident Medicine (AACC) board of directors in New York on Wednesday, 2 March 2017.

TL;DR: Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.

TL;DR: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non‐sex CHA2DS2‐VASc stroke risk factor(s), and stroke prevention (ie, oral antICOagulation therapy) is the next step.

TL;DR: The Atrial fibrillation Better Care pathway for integrated management provides a simple strategy (Avoid stroke, Better symptom management, and Cardiovascular and comorbidity risk reduction) that helps to improve awareness and detection.